Exendin-4 Anti-Inflammatory Pleiotropy: Decoding Molecular Signaling Pathways from Metabolic Control to Tissue Protection

Exendin-4 (Ex-4), clinically known in its synthetic form as exenatide, is a robust agonist of the glucagon-like peptide-1 receptor (GLP-1R) [1]. While it shares only 53% sequence homology with human GLP-1, its resistance to dipeptidyl peptidase-4 (DPP-4) degradation grants it a significantly longer half-life, making it a superior candidate for chronic therapeutic use [2]. Initially approved for the treatment of Type 2 Diabetes Mellitus (T2DM) due to its insulinotropic effects, recent evidence has shifted the focus toward its potent anti-inflammatory and cytoprotective capabilities [3, 4].

Inflammation is a common denominator in the progression of numerous chronic pathologies, from Alzheimer’s disease to atherosclerosis [5,6]. Exendin-4 has been shown to traverse the blood-brain barrier (BBB) and exert direct effects on immune cells, including macrophages and microglia, thereby modulating the systemic and local inflammatory microenvironment [5,7].

Molecular Mechanisms of Anti-inflammatory Action

The anti-inflammatory efficacy of Exendin-4 is rooted in its ability to regulate diverse intracellular signaling cascades.

Inhibition of the NF-κB and NLRP3 Pathways

Activation of GLP-1R by Exendin-4 leads to a reduction in the phosphorylation of the p65 subunit of nuclear factor-kappa B (NF-κB), a master regulator of pro-inflammatory gene expression [8]. Furthermore, Ex-4 has been shown to inhibit the assembly of the NLRP3 inflammasome, subsequently reducing the maturation and release of pro-inflammatory cytokines such as IL-1β and IL-18 [3].

Figure 1: Graphical Abstract

Activation of SIRT1 and AMPK

Exendin-4 upregulates Silent Information Regulator 1 (SIRT1) and Adenosine Monophosphate-activated Protein Kinase (AMPK) signaling [9,10]. In hepatic and renal models, this axis is critical for reducing endoplasmic reticulum (ER) stress and lipotoxicity-induced inflammation [10,11]. SIRT1 activation also facilitates the deacetylation of NF-κB, further suppressing the inflammatory response [9].

Modulation of MAPK and JNK

While Exendin-4 can transiently activate Mitogen-Activated Protein Kinases (MAPKs) to promote cell survival and differentiation [12], chronic administration in inflammatory contexts typically attenuates the phosphorylation of p38 MAPK and c-Jun N-terminal kinase (JNK) [6,13]. This suppression is vital in protecting pancreatic β-cells and neurons from cytokine-induced apoptosis [13,14].

Therapeutic Potential Based on Metabolic Control

Therapeutic Potential in Neurodegenerative Diseases: Neuroinflammation is a hallmark of Parkinson's Disease (PD) and Alzheimer's Disease (AD). Exendin-4 has shown remarkable promise as a disease-modifying agent in these conditions:

• Parkinson’s Disease: Some clinical trials have demonstrated that Exendin-4 can improve motor and cognitive functions in PD patients [5]. Mechanistically, it promotes microglial polarization from the pro-inflammatory M1 phenotype to the reparative M2 phenotype [7]
• Alzheimer’s Disease: In AD models, Ex-4 reduces amyloid-β (Aβ) accumulation and suppresses microglial activation, thereby preserving synaptic integrity [5,15]
• Ischemic Stroke: Exendin-4 treatment after stroke has been shown to reduce brain water content and Evans blue extravasation by preserving BBB integrity via GLP-1R/AMPK-dependent inhibition of MMP-9 [7,8]

Pulmonary and Respiratory Health

Recent studies have identified GLP-1R expression in the lungs, positioning Exendin-4 as a potential treatment for obstructive airway diseases [4,15]:

• Asthma and COPD: Exendin-4 restores airway mucus homeostasis through the PKA-PPARγ-FOXA2 signaling pathway, reducing the excessive mucus production characteristic of chronic obstructive pulmonary disease (COPD) [15]
• Pneumonia: In diabetic models of pneumonia, Exendin-4 improves outcomes by blocking T1R2/T1R3-mediated inflammatory responses and reducing pathogen accumulation [1]

Cardiovascular and Renal Protection

Exendin-4 exerts protective effects on the vasculature and kidneys by mitigating oxidative stress and inflammatory cell infiltration:

• Atherosclerosis: It reduces macrophage adhesion to the endothelium, an early step in plaque formation, by downregulating adhesion molecules [6]
• Diabetic Nephropathy: In the kidney, Ex-4 attenuates lipid accumulation and fibrosis by activating the SIRT1/AMPK pathway and reducing pro-inflammatory cytokine levels in the renal cortex [10]

Systemic Inflammation and Sepsis

In models of acute systemic inflammation induced by lipopolysaccharide (LPS), Exendin-4 administration significantly decreases circulating concentrations of TNF-α, IL-6 and IFNγ. Interestingly, it also modulates neutropenia and prevents the hypoglycemia often associated with early sepsis, suggesting a role in stabilizing the host response during critical illness [16].

Conceivable Tissue Protection

Neuroprotection: The Microglial Switch: In the Central Nervous System (CNS), Ex-4 operates primarily by shifting the polarization of microglia-the brain's resident immune cells:

• Pathway: Upon crossing the blood-brain barrier, Ex-4 binds to GLP-1R on microglia, triggering the cAMP/PKA (protein kinase A) pathway [3,7]
• Mechanism: This activation inhibits the translocation of the NF-κB p65 subunit into the nucleus. Consequently, the production of pro-inflammatory mediators like TNF-\alpha and NO (nitric oxide) is slashed [8]
• The M1/M2 Shift: Ex-4 promotes the M2 phenotype (anti-inflammatory/reparative) over the M1 phenotype (pro-inflammatory). This is mediated via the PI3K/Akt signaling axis, which enhances the expression of neurotrophic factors like BDNF [3,5]

Cardiovascular System: Vascular Integrity

Ex-4 mitigates atherosclerosis and myocardial injury by targeting the endothelium and cardiac macrophages:

• AMPK/SIRT1 Axis: Ex-4 activates AMPK (AMP-activated protein kinase), which in turn upregulates SIRT1. This duo is critical for inhibiting the NLRP3 inflammasome [10]
• Adhesion Molecule Suppression: By inhibiting the NF-κB pathway in endothelial cells, Ex-4 reduces the expression of VCAM-1 and ICAM-1. This prevents the "velcro effect" where monocytes stick to vessel walls, effectively slowing plaque formation [6]
• Oxidative Stress: Ex-4 enhances the activity of antioxidant enzymes like Superoxide Dismutase (SOD) via the Epac/Rap1 pathway, protecting cardiomyocytes from oxidative bursts during ischemia-reperfusion [2]

Renal Protection: Defeating Fibrosis

In the kidneys, inflammation often leads to irreversible fibrosis. Ex-4 steps in as a "fibro-suppressant":

• TGF-β/Smad Signaling: One of the most vital pathways Ex-4 modulates is the inhibition of TGF-β1 (transforming growth factor-beta 1). By suppressing Smad3 phosphorylation, Ex-4 prevents the transition of healthy renal cells into myofibroblasts [10,17]
• MCP-1 Inhibition: Ex-4 reduces the levels of Monocyte Chemoattractant Protein-1 (MCP-1) in the renal cortex. This prevents the mass migration of macrophages into the kidneys, which is a primary driver of diabetic nephropathy [10]
• Lipid Homeostasis: Through the SIRT1/PGC-1α axis, Ex-4 improves mitochondrial biogenesis in tubular cells, reducing the "lipotoxicity" that triggers local inflammatory responses [9,10]

Pulmonary System: Mucus and Airway Tone

The lungs possess a high density of GLP-1Rs, particularly in the airway smooth muscle and epithelial cells:

• The PKA-PPARγ-FOXA2 Axis: This is perhaps the most unique pathway for Ex-4. In chronic obstructive pulmonary disease (COPD) or asthma, the transcription factor FOXA2 is often suppressed, leading to mucus overproduction (goblet cell hyperplasia). Ex-4 activates PKA, which stabilizes PPARγ, ultimately restoring FOXA2 expression and shutting down the MUC5AC gene (the primary mucus gene) [4]
• T1R2/T1R3 Modulation: In cases of bacterial pneumonia, Ex-4 has been shown to block the T1R2/T1R3 "sweet taste" receptors on the airway surface, which bacteria often hijack to suppress host immune defense [1]

Summary of molecular targets is shown in Table 1.

Table 1: Summary of Molecular Targets by Organ

Future Perspectives: Engineering the Next Generation of Exendin-4 Therapies

While the molecular efficacy of Exendin-4 (Ex-4) across vital organs is well-documented, its clinical translation faces hurdles: a relatively short half-life compared to weekly GLP-1R agonists, gastrointestinal side effects and the challenge of achieving high therapeutic concentrations in the central nervous system (CNS) [2,3]. The future of Ex-4 therapy lies in the intersection of molecular biology and advanced bioengineering.

Nanotechnology and Enhanced CNS Delivery

To fully harness the neuroprotective potential of Ex-4 in diseases like Alzheimer’s and Parkinson’s, crossing the blood-brain barrier (BBB) more efficiently is paramount:

• Targeted Nanocarriers: Current research is pivoting toward ligand-functionalized nanoparticles (e.g., gold, PLGA or liposomes) that can be "tagged" to recognize specific receptors on the BBB [18]. These carriers protect the peptide from peripheral degradation and ensure a concentrated release directly into the brain parenchyma

Intranasal Delivery: Future clinical models are exploring the nose-to-brain pathway, utilizing mucoadhesive nanogels to bypass the systemic circulation entirely, thereby reducing the nausea and vomiting often associated with GLP-1R activation [5,7]

Sustained-Release Systems and Localized Therapy

Chronic inflammatory conditions like diabetic nephropathy or COPD require long-term, stable drug levels:

• Injectable Hydrogels: Researchers are developing thermosensitive hydrogels that can be injected subcutaneously or even locally (near a damaged organ). These gels act as a reservoir, releasing Ex-4 over weeks or months, maintaining the activation of the AMPK/SIRT1 axis without the "peaks and valleys" of daily injections [10,19]
• Oral Delivery Breakthroughs: Engineering pH-sensitive nanocapsules or using "microneedle" capsules could revolutionize Ex-4 therapy, shifting it from an injectable to an oral daily pill, which would significantly increase patient compliance in early-stage inflammatory diseases [20]

Synergistic Combination Therapies

The next frontier involves "molecular cocktails" where Ex-4 is paired with other small molecules to create a synergistic anti-inflammatory effect:

• Ex-4+SGLT2 Inhibitors: Preliminary data suggest that combining Ex-4 with SGLT2 inhibitors may provide superior renal protection by simultaneously targeting hemodynamic stress and the TGF-β/Smad inflammatory pathway [10]
• Ex-4+Curcumin/Resveratrol: Co-delivery with natural SIRT1 activators could amplify the deacetylation of NF-κB, leading to a more profound suppression of the "cytokine storm" in systemic conditions like sepsis [9,16]

1. Yu, S. et al. “Exendin-4 Blockade of T1R2/T1R3 Activation Improves Pseudomonas aeruginosa-Related Pneumonia in an Animal Model of Chemically Induced Diabetes.” Inflammation Research, vol. 73, no. 10, 2024, pp. 1185-1201. https://doi.org/1 0.1007/s00011-024-01891-8.

2. El-Sayed Hassan, A. et al. “Beyond Glycemic Control: Exploring the Prospective of Exendin-4 Clinical Utility as a Disease-Modifying Agent in Alzheimer’s Disease; Preclinical and Clinical Evidence.” Journal of Pioneering Medical Sciences, vol. 15, no. 3, 2026, pp. 44-47. https://doi.org/10. 47310/jpms2026150307.

3. Diz-Chaves, Y. et al. “Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases.” International Journal of Molecular Sciences, vol. 23, no. 17, 2022. https://doi.org/10.3390/ijms23179583.

4. Choi, W. et al. “Exendin-4 Restores Airway Mucus Homeostasis through the GLP1R-PKA-PPARγ-FOXA2-Phosphatase Signaling.” Mucosal Immunology, vol. 13, no. 4, 2020, pp. 637-651. https://doi.org/10.1038/s41385-020-0262-1.

5. Figat, M. et al. “Beneficial Influence of Exendin-4 on Specific Organs and Mechanisms Favourable for the Elderly with Concomitant Obstructive Lung Diseases.” Brain Sciences, vol. 12, no. 8, 2022. https://doi.org/10.3390/brainsci12081090.

6. Arakawa, M. et al. “Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-Like Peptide-1 Receptor Agonist, Exendin-4.” Diabetes, vol. 59, no. 4, 2010, pp. 1030-1037. https://doi. org/10.2337/db09-1694.

7. El-Sayed Hassan, A. et al. “Exendin-4 Emerging Therapeutic Potential in Dermatology.” Journal of Pioneering Medical Sciences, vol. 15, no. 2, 2026, pp. 93-95. https://doi.org/10. 47310/jpms2026150212.

8. Xie, Z. et al. “Exendin-4 Preserves Blood-Brain Barrier Integrity via Glucagon-Like Peptide 1 Receptor/Activated Protein Kinase-Dependent Nuclear Factor-Kappa B/Matrix Metalloproteinase-9 Inhibition after Subarachnoid Hemorrhage in Rat.” Frontiers in Molecular Neuroscience, vol. 14, 2021. https://doi.org/10.3389/fnmol.2021.750726.

9. Wang, A. et al. “Exendin-4 Upregulates Adiponectin Level in Adipocytes via Sirt1/Foxo-1 Signaling Pathway.” PLOS ONE, vol. 12, no. 1, 2017. https://doi.org/10.1371/journal. pone.0169469.

10. Lee, J. et al. “Exendin-4 Attenuates Endoplasmic Reticulum Stress through a SIRT1-Dependent Mechanism.” Cell Stress & Chaperones, vol. 19, no. 5, 2014, pp. 649-656. https://doi. org/10.1007/s12192-013-0490-3.

11. Himeno, T. et al. “Beneficial Effects of Exendin-4 on Experimental Polyneuropathy in Diabetic Mice.” Diabetes, vol. 60, no. 9, 2011, pp. 2397-2406. https://doi.org/10.2337/db 10-1462.

12. Wang, M. et al. “Exendin-4 Regulates the MAPK and WNT Signaling Pathways to Alleviate the Osteogenic Inhibition of Periodontal Ligament Stem Cells in a High Glucose Environment.” Open Medicine, vol. 18, no. 1, 2023. https:// doi.org/10.1515/med-2023-0692.

13. Lee, J. et al. “Exendin-4 Inhibits the Expression of SEPP1 and Fetuin-A via Improvement of Palmitic Acid-Induced Endoplasmic Reticulum Stress by AMPK.” Endocrinology and Metabolism, vol. 30, no. 2, 2015, pp. 177-184. https://doi. org/10.3803/EnM.2015.30.2.177.

14. Lee, J. et al. “Exendin-4 Improves Steatohepatitis by Increasing Sirt1 Expression in High-Fat Diet-Induced Obese C57BL/6J Mice.” PLOS ONE, vol. 7, no. 2, 2012. https://doi. org/10.1371/journal.pone.0031394.

15. Xu, Y. et al. “Exendin-4 Reduces Senescence of Inflammation-Induced Periodontal Ligament Stem Cells through SIRT1/Notch1 Signaling.” Stem Cells International, 2025. https://doi.org/10.1155/sci/7639451.

16. Yanay, O. et al. “Effects of Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, on Neutrophil Count and Inflammatory Cytokines in a Rat Model of Endotoxemia.” Journal of Inflammation Research, vol. 8, 2015, pp. 129-135. https://doi.org/10.2147/JIR.S84993.

17. Zhou, H. et al. “Effects of Exendin-4 on Bone Marrow Mesenchymal Stem Cell Proliferation, Migration and Apoptosis in Vitro.” Scientific Reports, vol. 5, 2015. https:// doi.org/10.1038/srep12898.

18. Huang, Y. et al. “Exenatide-Modified Deferoxamine-Based Nanoparticles Ameliorates Neurological Deficits in Parkinson’s Disease Mice.” International Journal of Nanomedicine, vol. 19, 2024, pp. 10401-10414. https://doi. org/10.2147/IJN.S479670.

19. Spezani, R. and C.A. Mandarim-de-Lacerda. “Beyond Diabetes and Obesity: GLP-1 Receptor Agonists in Disrupting the Vicious Cycle of Metabolic Dysfunction and Neuroinflammation.” Diabetes, Obesity & Metabolism, vol. 28, no. 3, 2026, pp. 1622-1637. https://doi.org/10.1111/dom. 70400.

20. Del Olmo-Garcia, M.I. and J.F. Merino-Torres. “GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes.” Journal of Diabetes Research, 2018. https://doi.org/10.1155/2018/4020492.